<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23551" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Inotropes and Vasopressors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>VanValkinburgh</surname>
            <given-names>Danny</given-names>
          </name>
          <aff>University of Tennessee HSC COM Memphis</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kerndt</surname>
            <given-names>Connor C.</given-names>
          </name>
          <aff>Spectrum Health/Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Danny VanValkinburgh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Connor Kerndt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23551.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Vasopressors and inotropes are medications used to create vasoconstriction or increase cardiac contractility, respectively, in patients with shock. The hallmark of shock is decreased perfusion to vital organs, resulting in multiorgan dysfunction and eventually death. Vasopressors increase vasoconstriction, which leads to increased systemic vascular resistance (SVR). Increasing the SVR leads to increased mean arterial pressure (MAP) and increased perfusion to organs. Inotropes increase cardiac contractility, which improves cardiac output (CO), aiding in maintaining MAP and perfusion to the body. This activity describes the mode of action of inotropes and vasopressors, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, and monitoring, and highlights the role of the interprofessional team in the management of conditions where vasopressors and inotropes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanisms of action of various inotropes and vasopressors.</p></list-item><list-item><p>Review the indications for initiating inotropic and/or vasopressor therapy.</p></list-item><list-item><p>Outline the contraindications for initiating vasopressive and inotropic therapy.</p></list-item><list-item><p>Explain the importance of collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients receiving treatment with inotropes and vasopressors.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23551&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23551">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23551.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Vasopressors and inotropes are medications used to create vasoconstriction or increase cardiac contractility, respectively, in patients with shock or any other reason for extremely low blood pressure. The hallmark of shock is decreased perfusion to vital organs, resulting in multiorgan dysfunction and eventually death.</p>
        <p>Vasopressors increase vasoconstriction, which leads to increased systemic vascular resistance (SVR). Increasing the SVR leads to increased mean arterial pressure (MAP) and increased perfusion to organs. Inotropes increase cardiac contractility, which improves cardiac output (CO), aiding in maintaining MAP and perfusion to the body. The equation that connects the 2 is MAP= CO x SVR.</p>
        <p>Indications for vasopressors and inotropes in patients with shock vary on the etiology and type of shock occurring in the patient. There are&#x000a0;four main types of shock: hypovolemic, distributive, cardiogenic, and obstructive. Each type has its indications for vasopressors and inotropes. However, most of these medications&#x000a0;are viable options in each scenario. Each of the major medications will be discussed briefly.</p>
        <p>The major vasopressors include phenylephrine, norepinephrine, epinephrine, and vasopressin. Dopamine is a vasopressor with inotrope properties that is dose-dependent. Dobutamine and milrinone are inotropes.<xref ref-type="bibr" rid="article-23551.r1">[1]</xref></p>
        <p>Distributive shock is commonly caused by sepsis, neurogenic shock, and anaphylaxis. These types of shock are caused by a leaky or dilated vascular system that leads to a low SVR state. The goal of vasopressors in this situation is to increase the SVR by direct constriction of the vessels.&#x000a0;</p>
        <p>The American College of Critical Care Medicine (ACCM) guidelines recognize that a MAP of 60 to 65 mm Hg is required to perfuse organs. If, after appropriate fluid resuscitation, the MAP does not improve to about 60 mm Hg, it is recommended that vasopressors be initiated. Norepinephrine is recommended as the initial vasopressor per the Surviving Sepsis Campaign recommendations. Vasopressin or epinephrine are the two recommended vasopressors to add to norepinephrine, although the evidence for these recommendations is considered weak.<xref ref-type="bibr" rid="article-23551.r2">[2]</xref></p>
        <p>Neurogenic shock secondary to spinal injury or disease of the spinal cord results in a lack of sympathetic tone of the peripheral nerves and unopposed parasympathetic activation. Uninhibited vagal tone results in vasogenic and cardiogenic instability. Initial stabilization requires a fluid challenge to restore intravascular volume. If hypotension persists, vasopressors are indicated to maintain systolic blood pressure greater than 90 mm Hg or MAP 85 to 90 mm Hg for the first 7 days. Norepinephrine is recommended as the initial pressor for alpha and beta activation. Epinephrine may be added as a secondary pressor. Phenylephrine should be used with extreme caution because of the reflex bradycardia due to unopposed vagal action on the heart, which may be associated with its use.<xref ref-type="bibr" rid="article-23551.r3">[3]</xref></p>
        <p>Cardiogenic shock most commonly occurs in the setting of acute myocardial infarction. The cardiac output is diminished as well as decreased diastolic blood pressure. Decreasing both CO and DBP causes increasing hypoperfusion and organ dysfunction, which leads to worsening cardiac damage. Initial management is a fluid challenge of 250 to 500 mL. Persistent hypotension requires adding inotropes or vasopressors. The AHA 2017 recommendations for cardiogenic shock state states&#x000a0;little clinical outcome data exist despite the prevalence of use for these agents. No MAP or blood pressure minimum has been extensively studied, but a reasonable goal is a MAP of 65 mm Hg.<xref ref-type="bibr" rid="article-23551.r4">[4]</xref>&#x000a0;Some studies have shown that norepinephrine&#x000a0;results in fewer dysrhythmia events compared to dopamine which has classically been the primary choice. The AHA suggests choosing vasopressors or inotropes as needed based on clinical scenarios and etiology.</p>
      </sec>
      <sec id="article-23551.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Vasopressors act to increase CO and SVR through increasing contractility and HR as well inducing vasoconstriction peripherally.<xref ref-type="bibr" rid="article-23551.r5">[5]</xref>&#x000a0;The main groupings of these drugs are as follows:</p>
        <p>
<bold>Catecholamines</bold>
</p>
        <p>The most common catecholamine-active medications are phenylephrine, norepinephrine, and epinephrine. Other agents in this class include isoproterenol, dobutamine, and dopamine. Each of these three medications has varying activity on the alpha and beta receptors. Alpha receptors are peripheral vasoconstrictors to increase SVR. Beta-1 receptors have mostly positive chronotropic (heart rate) and inotropic (contractility) effects on the heart. Beta-2 receptors act as vasodilators in many organ systems.<xref ref-type="bibr" rid="article-23551.r6">[6]</xref><xref ref-type="bibr" rid="article-23551.r7">[7]</xref></p>
        <p>Phenylephrine is a pure alpha-1 agonist, inducing peripheral arterial vasoconstriction. Reflex bradycardia may occur due to selective vasoconstriction and elevation of blood pressure. Blood pressure, MAP, and SVR are increased.&#x000a0;<xref ref-type="bibr" rid="article-23551.r5">[5]</xref>Norepinephrine has mixed alpha-1 and beta activity (beta-1 greater than beta-2), with slightly more alpha-1 activity&#x000a0;than beta activity. This leads to a more significant increase in blood pressure than increased HR. Blood pressure, MAP, SVR, and CO are increased with norepinephrine.<xref ref-type="bibr" rid="article-23551.r6">[6]</xref></p>
        <p>Epinephrine has essentially comparable activity on alpha-1 and beta receptors. Epinephrine increases systemic vascular resistance, heart rate, cardiac output, and blood pressure.<xref ref-type="bibr" rid="article-23551.r6">[6]</xref><xref ref-type="bibr" rid="article-23551.r1">[1]</xref></p>
        <p>Isoproterenol is an isopropylamine analog of epinephrine used in bradyarrhythmias (such as torsades des pointes) and Brugada syndrome.<xref ref-type="bibr" rid="article-23551.r7">[7]</xref></p>
        <p>Dopamine is a precursor of norepinephrine and epinephrine, which acts in a dose-dependent fashion on dopaminergic receptors as well as alpha and beta receptors. At low doses, dopaminergic receptors activate renal artery vasodilation. At doses 5 to 15 micrograms/kg/min, alpha and beta-adrenergic activation increase renal blood flow, HR, contractility, and CO. At higher doses greater than 15 micrograms/kg per minute, the main effects are on alpha stimulation.<xref ref-type="bibr" rid="article-23551.r6">[6]</xref></p>
        <p>Dobutamine increases CO mostly through its effects on beta and alpha stimulation. Dobutamine has an affinity for beta-1 greater than beta-2 greater than alpha. Dobutamine increases contractility and CO with minimal effects on BP.<xref ref-type="bibr" rid="article-23551.r6">[6]</xref><xref ref-type="bibr" rid="article-23551.r1">[1]</xref>&#x000a0;Dobutamine is also used in cardiac stress testing.<xref ref-type="bibr" rid="article-23551.r8">[8]</xref></p>
        <p>
<bold>Vasopressin</bold>
</p>
        <p>Vasopressin acts on V-1 receptors to stimulate smooth muscle contraction of the vessels as well as V-2 receptors in the kidneys as an anti-diuretic. There are no inotropic or chronotropic effects. Only BP and SVR are increased with vasopressin.<xref ref-type="bibr" rid="article-23551.r6">[6]</xref></p>
        <p>
<bold>Phosphodiesterase Inhibitors</bold>
</p>
        <p>Milrinone is a phosphodiesterase inhibitor that causes increased levels of cyclic AMP. In cardiac myocytes, this&#x000a0;results in cardiac stimulation and increased CO. cAMP has vasodilatory effects in the smooth peripheral vessels leading to vasodilation and decreased BP. Milrinone is used to treat low CO as in decompensated HF.<xref ref-type="bibr" rid="article-23551.r9">[9]</xref><xref ref-type="bibr" rid="article-23551.r6">[6]</xref></p>
      </sec>
      <sec id="article-23551.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Vasopressors and inotropes are administered intravenously (IV). The method of choice for most of these medications is a continuous infusion that allows for immediate titration for desired effects. Although peripheral IVs are suitable for short-term use, adverse effects can and do occur. Although the absolute necessity for immediate central access has been recently brought into question, it is recognized that central access is the method of choice for administering vasoactive medications.<xref ref-type="bibr" rid="article-23551.r10">[10]</xref></p>
      </sec>
      <sec id="article-23551.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of vasopressors and inotropes depend on the mechanism of action. For the medications that have beta stimulation, arrhythmias are one of the most common adverse effects. Some of the specific adverse effects will be described here.</p>
        <p>Dopamine has various mechanisms and adverse effects that include hypotension, tachycardia, local tissue necrosis, and gangrene if extravasation occurs. Epinephrine can have tachycardia, anxiety, pulmonary edema, and local tissue necrosis with extravasation. Norepinephrine has similar adverse effects to epinephrine but may also include bradycardia and dysrhythmia. Phenylephrine may cause reflex bradycardia, decreased CO, local tissue necrosis with extravasation, peripheral, renal, mesenteric, or myocardial ischemia. Vasopressin may induce arrhythmias, mesenteric ischemia, chest pain, coronary artery constriction and MI, bronchial constriction, hyponatremia, and local tissue necrosis with extravasation.<xref ref-type="bibr" rid="article-23551.r7">[7]</xref></p>
        <p>Adverse effects of inotropes include hypertension, hypotension, dysrhythmias, angina, and acute MI. Dobutamine, specifically, may cause hypokalemia and local tissue necrosis with extravasation.<xref ref-type="bibr" rid="article-23551.r11">[11]</xref> Dobutamine has also been associated with increased mortality with prolonged use, likely due to its effect of increased myocardial oxygen consumption, which may limit its clinical effectiveness.&#x000a0;Milrinone may cause elevated LFTs, thrombocytopenia, and increased mortality with long-term use.</p>
      </sec>
      <sec id="article-23551.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Few absolute contraindications exist for vasopressors and inotropes outside of anaphylactic hypersensitivity reactions. Adrenergic agents are contraindicated with halogenated hydrocarbons like halothane during general anesthesia<xref ref-type="bibr" rid="article-23551.r6">[6]</xref>. In certain situations, there are relative contraindications to dopamine, dobutamine, and milrinone. It is recommended dopamine not be used as the first-line vasopressor in septic shock compared to norepinephrine due to increased mortality and increased dysrhythmias.<xref ref-type="bibr" rid="article-23551.r12">[12]</xref> Adrenergic vasopressors should be avoided in patients with pheochromocytoma or uncorrected tachyarrhythmia. Dobutamine is contraindicated in idiopathic hypertrophic subaortic stenosis. Some organizations also have dobutamine as a relative contraindication in patients with recent MI or a history of uncontrolled BP, aortic dissection, or a large aortic aneurysm. Patients taking an MAOI should have decreased doses and be monitored closely.</p>
      </sec>
      <sec id="article-23551.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>All patients requiring vasopressors or inotropes require close monitoring of vital signs, fluid status, and laboratory markers. Arterial blood pressure monitoring via catheter allows for immediate recognition of changes and allows for precise titration. Pulmonary artery catheters may be considered to assess cardiac function. Continuous cardiac monitoring for dysrhythmias is essential. For patients who can speak, frequent checks for pain at the vascular access site, chest pain, peripheral numbness, abdominal pain, and neuro checks should be performed. Evaluation of peripheral ischemia should be frequent. Laboratory markers for worsening perfusion status and multiorgan injury should be closely monitored. Vasopressin&#x02019;s effect on renal function requires close monitoring of serum and urine sodium, osmolality, and fluid status. Milrinone requires monitoring of LFTs and platelet count.<xref ref-type="bibr" rid="article-23551.r6">[6]</xref></p>
      </sec>
      <sec id="article-23551.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Patients currently taking a MAOI will have decreased metabolism of adrenergic vasopressors and will require lower doses to avoid toxicity.<xref ref-type="bibr" rid="article-23551.r6">[6]</xref></p>
        <p>Most of the medications mentioned above are naturally occurring compounds. There are no common toxicological issues directly related to the medications, metabolites, or preparations of the medications described above.<xref ref-type="bibr" rid="article-23551.r13">[13]</xref><xref ref-type="bibr" rid="article-23551.r14">[14]</xref></p>
      </sec>
      <sec id="article-23551.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Inotropes and vasopressors are commonly used in the ICU. Since the conditions they address and the effects they render can be critical, an entire interprofessional team should be involved in their ordering, dosing, and administration, as well as subsequent monitoring. While these medications are ordered by clinicians, the monitoring of the patient is done by nurses trained in critical care. Pharmacists should verify dosing and check for interactions and contraindications to their use. Besides vital signs, patient body weight, fluid status, renal function, and peripheral perfusion require continuous monitoring. A constant assessment of the patient is needed to ensure that the inotropes and vasopressors are tapered if not needed.<xref ref-type="bibr" rid="article-23551.r15">[15]</xref><xref ref-type="bibr" rid="article-23551.r16">[16]</xref>&#x000a0;These examples of interprofessional coordination can improve outcomes when patients receive vasopressive and inotropic medications with fewer adverse events. [Level 5]</p>
      </sec>
      <sec id="article-23551.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23551&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23551">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23551/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23551">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23551.s11">
        <title>References</title>
        <ref id="article-23551.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Einav</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Helviz</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ippolito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cortegiani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vasopressor and inotrope treatment for septic shock: An umbrella review of reviews.</article-title>
            <source>J Crit Care</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>65</volume>
            <fpage>65</fpage>
            <page-range>65-71</page-range>
            <pub-id pub-id-type="pmid">34090150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hollenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ahrens</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Annane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Astiz</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Chalfin</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Dasta</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Heard</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Susla</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Totaro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Zanotti-Cavazzoni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update.</article-title>
            <source>Crit Care Med</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>9</issue>
            <fpage>1928</fpage>
            <page-range>1928-48</page-range>
            <pub-id pub-id-type="pmid">15343024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dave</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dahlstrom</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Weisbrod</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <chapter-title>Neurogenic Shock</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">29083597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Diepen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Kilic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sweitzer</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Washam</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>MG</given-names>
              </name>
              <collab>American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Mission: Lifeline</collab>
            </person-group>
            <article-title>Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Oct</month>
            <day>17</day>
            <volume>136</volume>
            <issue>16</issue>
            <fpage>e232</fpage>
            <page-range>e232-e268</page-range>
            <pub-id pub-id-type="pmid">28923988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russell</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Vasopressor therapy in critically ill patients with shock.</article-title>
            <source>Intensive Care Med</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>45</volume>
            <issue>11</issue>
            <fpage>1503</fpage>
            <page-range>1503-1517</page-range>
            <pub-id pub-id-type="pmid">31646370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Review and update on inotropes and vasopressors.</article-title>
            <source>AACN Adv Crit Care</source>
            <year>2008</year>
            <season>Jan-Mar</season>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-13; quiz 14-5</page-range>
            <pub-id pub-id-type="pmid">18418098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Overgaard</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Dzav&#x000ed;k</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease.</article-title>
            <source>Circulation</source>
            <year>2008</year>
            <month>Sep</month>
            <day>02</day>
            <volume>118</volume>
            <issue>10</issue>
            <fpage>1047</fpage>
            <page-range>1047-56</page-range>
            <pub-id pub-id-type="pmid">18765387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sengupta</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Mungulmare</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okwose</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>MacGowan</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Jakovljevic</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Comparison of cardiac output estimates by echocardiography and bioreactance at rest and peak dobutamine stress test in heart failure patients with preserved ejection fraction.</article-title>
            <source>Echocardiography</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>1603</fpage>
            <page-range>1603-1609</page-range>
            <pub-id pub-id-type="pmid">32949037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverman</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Houston</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Tedford</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Old Drug, New Trick? Oral Milrinone for Heart Failure With Preserved Ejection Fraction.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2020</year>
            <month>Jul</month>
            <day>07</day>
            <volume>9</volume>
            <issue>13</issue>
            <fpage>e017170</fpage>
            <pub-id pub-id-type="pmid">32552221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardenas-Garcia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schaub</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Belchikov</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Narasimhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Mayo</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Safety of peripheral intravenous administration of vasoactive medication.</article-title>
            <source>J Hosp Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>581</fpage>
            <page-range>581-5</page-range>
            <pub-id pub-id-type="pmid">26014852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coma-Canella</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Changes in plasma potassium during the dobutamine stress test.</article-title>
            <source>Int J Cardiol</source>
            <year>1991</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-9</page-range>
            <pub-id pub-id-type="pmid">1937984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Backer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arias Ortiz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The medical treatment of cardiogenic shock: cardiovascular drugs.</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2021</year>
            <month>Aug</month>
            <day>01</day>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>426</fpage>
            <page-range>426-432</page-range>
            <pub-id pub-id-type="pmid">33797431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sionis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rivas-Lasarte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mebazaa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarvasm&#x000e4;ki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sans-Rosell&#x000f3;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tolppanen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Varpula</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jurkko</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Banaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silva-Cardoso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carubelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lindholm</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Parissis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spinar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lassus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harjola</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Masip</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Current Use and Impact on 30-Day Mortality of Pulmonary Artery Catheter in Cardiogenic Shock Patients: Results From the CardShock Study.</article-title>
            <source>J Intensive Care Med</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>1426</fpage>
            <page-range>1426-1433</page-range>
            <pub-id pub-id-type="pmid">30732522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kislitsina</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Churyla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vorovich</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Ghafourian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Shock - Classification and Pathophysiological Principles of Therapeutics.</article-title>
            <source>Curr Cardiol Rev</source>
            <year>2019</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-113</page-range>
            <pub-id pub-id-type="pmid">30543176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaufmann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Scheeren</surname>
                <given-names>TWL</given-names>
              </name>
              <name>
                <surname>Saugel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Keus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van der Horst</surname>
                <given-names>ICC</given-names>
              </name>
            </person-group>
            <article-title>Perioperative goal-directed therapy: A systematic review without meta-analysis.</article-title>
            <source>Acta Anaesthesiol Scand</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>1340</fpage>
            <page-range>1340-1355</page-range>
            <pub-id pub-id-type="pmid">29978454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23551.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Annane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ouanes-Besbes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Backer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>DU</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Osborn</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Peake</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cavazzoni</surname>
                <given-names>SZ</given-names>
              </name>
            </person-group>
            <article-title>A global perspective on vasoactive agents in shock.</article-title>
            <source>Intensive Care Med</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>833</fpage>
            <page-range>833-846</page-range>
            <pub-id pub-id-type="pmid">29868972</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
